PMID- 20417687 OWN - NLM STAT- MEDLINE DCOM- 20100729 LR - 20220311 IS - 1872-7972 (Electronic) IS - 0304-3940 (Linking) VI - 477 IP - 1 DP - 2010 Jun 14 TI - Effect of analgesic standards on persistent postoperative pain evoked by skin/muscle incision and retraction (SMIR). PG - 43-7 LID - 10.1016/j.neulet.2010.04.033 [doi] AB - Various common surgeries such as thoracotomy and inguinal hernia repair involve essential prolonged tissue retraction, often causing persistent postoperative pain. A new model was developed to mimic this clinical scenario, whereby skin/muscle incision and retraction (SMIR) in the medial thigh evoked persistent postoperative pain (Flatters (2008) [Pain 135:119-130]). This study examines the response of SMIR-evoked mechanical hypersensitivity to analgesic standards commonly used as positive controls in behavioural pain studies. Rats were anaesthetised, the skin and superficial muscle of the medial thigh was then incised and retracted for 1h. In separate experiments, morphine, gabapentin and MK-801 were intraperitoneally administered to SMIR-operated rats, at maximally tolerated doses, on postoperative day 9-13. Mechanical hypersensitivity was measured by withdrawal responses to von Frey stimulation of the plantar hindpaws. Morphine (6mg/kg) and gabapentin (100mg/kg) elicited an almost complete reversal of SMIR-evoked mechanical hypersensitivity. In contrast, MK-801 (0.1mg/kg) did not affect SMIR-evoked mechanical hypersensitivity. Contralateral hindpaw responses to von Frey stimulation were unaffected by SMIR surgery or any drug treatment. In conclusion, the SMIR model displays persistent mechanical hypersensitivity that is reversible by morphine or gabapentin treatment. As previously demonstrated, SMIR-evoked pain is not driven by neuronal damage and these data show that NMDA receptor activation does not play a role in the maintenance of SMIR-evoked pain. This study further demonstrates the value of the SMIR model as a tool to understand persistent postoperative/postsurgical pain mechanisms and evaluate potential treatments. CI - 2010 Elsevier Ireland Ltd. All rights reserved. FAU - Flatters, Sarah J L AU - Flatters SJ AD - Wolfson Centre for Age-Related Diseases, Centre for Integrative Biomedicine, King's College London, Hodgkin Building, Guy's Campus, London SE11UL, UK. sarah.flatters@kcl.ac.uk LA - eng GR - BB/E527098/1/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20100424 PL - Ireland TA - Neurosci Lett JT - Neuroscience letters JID - 7600130 RN - 0 (Amines) RN - 0 (Analgesics) RN - 0 (Cyclohexanecarboxylic Acids) RN - 56-12-2 (gamma-Aminobutyric Acid) RN - 6CW7F3G59X (Gabapentin) RN - 6LR8C1B66Q (Dizocilpine Maleate) RN - 76I7G6D29C (Morphine) SB - IM MH - Amines/therapeutic use MH - Analgesics/*therapeutic use MH - Animals MH - Chronic Disease MH - Cyclohexanecarboxylic Acids/therapeutic use MH - *Dermatologic Surgical Procedures MH - *Disease Models, Animal MH - Dizocilpine Maleate/therapeutic use MH - Gabapentin MH - Hindlimb MH - Hyperalgesia/drug therapy/physiopathology MH - Male MH - Morphine/therapeutic use MH - Muscle, Skeletal/*surgery MH - Pain Measurement MH - Pain, Postoperative/drug therapy/*physiopathology MH - Rats MH - Rats, Sprague-Dawley MH - Touch MH - gamma-Aminobutyric Acid/therapeutic use EDAT- 2010/04/27 06:00 MHDA- 2010/07/30 06:00 CRDT- 2010/04/27 06:00 PHST- 2010/03/16 00:00 [received] PHST- 2010/04/14 00:00 [revised] PHST- 2010/04/16 00:00 [accepted] PHST- 2010/04/27 06:00 [entrez] PHST- 2010/04/27 06:00 [pubmed] PHST- 2010/07/30 06:00 [medline] AID - S0304-3940(10)00480-5 [pii] AID - 10.1016/j.neulet.2010.04.033 [doi] PST - ppublish SO - Neurosci Lett. 2010 Jun 14;477(1):43-7. doi: 10.1016/j.neulet.2010.04.033. Epub 2010 Apr 24.